TLDR compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles

    KY19382 is a compound that has garnered attention within the field of hair loss research for its potential to not only promote hair regrowth but also to facilitate the creation of new hair follicles. Its history is rooted in the scientific exploration of pathways that can be targeted to combat hair loss, specifically through the activation of the Wnt/β-catenin signaling pathway. This pathway plays a crucial role in the regulation of hair follicle development and cycling, making it a prime target for interventions aimed at treating alopecia.

    The role of KY19382 in the context of alopecia, hair growth, or hair loss centers around its ability to activate the Wnt/β-catenin signaling pathway. By doing so, it influences various factors critical for hair growth, such as increasing the expression of alkaline phosphatase (ALP) and the proliferation marker PCNA in dermal papilla cells. This activation not only enhances hair length in ex vivo-cultured mouse vibrissa and human hair follicles but also induces significant hair regrowth and the formation of new hair follicles in vivo, making it a promising candidate for alopecia treatments.

    Research on KY19382 has shown its effectiveness in promoting hair regrowth and hair follicle neogenesis. Studies conducted have observed its ability to activate Wnt/β-catenin signaling in both human and rat dermal papilla cells, a key mechanism through which it promotes hair growth. The compound's impact extends to increasing alkaline phosphatase activity, a marker of hair induction, and enhancing both wound-induced hair follicle neogenesis and hair follicle neogenesis in patch assays. Such findings suggest KY19382's potential utility in treating hair loss and baldness, highlighting its capacity to stimulate hair regrowth and the generation of new hair follicles.

    The community has recognized KY19382 among discussions of upcoming treatments, referencing it alongside other potential options like clascoterone, pyrilutamide, and GT20029. While direct experiences with KY19382 itself are not extensively documented within the community, its mention alongside other investigational treatments indicates an interest and hope in its future application for hair loss.


    10 / 10 NoResults


    12 / 12 NoResults